Erbitux 100 mg Cetuximab Price USA | Ernest Oncology Indian Exporter

Erbitux 100 mg Injection: Targeted EGFR Inhibition for Advanced Oncology Care

Are you searching for a dependable Erbitux 100 mg injection exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced monoclonal antibodies. We maintain a high-authority, cold-chain-compliant supply chain serving the USA, UK, Australia, and South Africa, ensuring that critical EGFR-targeted therapies reach healthcare providers with pharmaceutical-grade integrity and efficient global logistics.

Detailed Product Overview: What is Erbitux 100 mg?

Erbitux 100 mg Injection is a recombinant human/mouse chimeric monoclonal antibody containing the active ingredient Cetuximab. It is a precision medicine designed to target and inhibit the Epidermal Growth Factor Receptor (EGFR), which is often overexpressed in certain types of solid tumors.

For international B2B procurement, Erbitux 100 mg (supplied as a 100 mg/20 ml solution for infusion) provides a clinically validated solution for treating specific cancers that have not responded to standard chemotherapy.

Primary Therapeutic Indications

Erbitux 100 mg is clinically utilized globally for the following:

1. Metastatic Colorectal Cancer (mCRC): For patients with EGFR-expressing, RAS wild-type tumors, often used in combination with FOLFIRI or irinotecan.

2. Squamous Cell Carcinoma of the Head and Neck (SCCHN):

• In combination with radiation therapy for locally advanced disease.

• In combination with platinum-based chemotherapy for recurrent or metastatic disease.

• As a single agent for patients who have failed platinum-based therapy.

Mechanism of Action: How Cetuximab Works

Erbitux works through a targeted biological process known as EGFR inhibition:

• Receptor Blockade: Cetuximab binds specifically to the extracellular domain of the Epidermal Growth Factor Receptor (EGFR) on both normal and tumor cells.

• Signaling Interruption: By binding to EGFR, it competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, blocking the internal signaling pathways that tell the cancer cell to grow and multiply.

• Inducing Cell Death: This blockade leads to inhibition of cell growth, induction of apoptosis (programmed cell death), and a reduction in matrix metalloproteinase and vascular endothelial growth factor production.

• Immune Activation: It also encourages the body's immune system to attack the cancer cells through antibody-dependent cell-mediated cytotoxicity (ADCC).

Administration and Clinical Safety

• Infusion Protocol: Erbitux must be administered as an intravenous infusion by a healthcare professional. Pre-medication with an H1 antagonist (like diphenhydramine) is required to prevent infusion reactions.

• Cold-Chain Management: This biological product is temperature-sensitive and must be stored between 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze.

• Key Monitoring:

• Infusion Reactions: Monitoring is essential during and for one hour following the infusion.

• Dermatologic Toxicities: Patients frequently develop acneiform rash, which may require dose modification or topical treatments.

• Electrolyte Monitoring: Periodic monitoring of serum magnesium, calcium, and potassium is recommended.

Why Source Erbitux from Ernest Oncology?

• Authentic Indian Exporter: Direct access to genuine oncology inventory, providing 100% product authenticity and competitive wholesale pricing for international markets.

• Cold-Chain Authority: We utilize validated thermal shipping solutions and data loggers to ensure Erbitux remains within the required temperature range during transit to the USA, UK, Australia, and South Africa.

• Regulatory Compliance: We provide all essential B2B documentation, including GMP compliance, batch-specific COAs, and necessary export documentation.

• Bulk Supply Stability: We specialize in fulfilling large-scale orders for hospital groups, oncology clinics, and regional distributors.